Prometheus competitors

Paul J. Diaz, was named president, chief executive officer and member of the Myriad board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses. Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine. Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the Federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.

Tim joined Teligent Inc. as President and CEO in February 2020. He brings over 26 years of experience in the pharmaceutical industry, having held a variety of senior executive positions in general management, marketing and sales. Prior to joining Teligent, Tim spent 16 years at Barr Laboratories, eventually serving as Executive Vice President, Global Generic Sales and Marketing where he led a team of nearly 2,000 employees in 25 countries. Subsequently, Tim held positions of Senior Vice President, Corporate Strategic Development at Mylan, and President, Retail Medicine at 1-800-Doctors, Inc. Most recently, Tim served as Chief Executive Officer of Geritrex, LLC, a manufacturer and marketer of generic over the counter pharmaceuticals.